Alto Neuroscience, Inc. ( ANRO ) Nowojorska Giełda Papierów Wartościowych

Cena: 2.62 ( 1.36% )

Aktualizacja 07-10 21:58
Nowojorska Giełda Papierów Wartościowych
Branża: Biotechnology

Notowania:


Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 78
Giełda: Nowojorska Giełda Papierów Wartościowych
Ilość akcji w obrocie: 20%
Ilość akcji: 26 780 400
Debiut giełdowy: 2024-02-02
WWW: https://www.altoneuroscience.com
CEO: Dr. Amit Etkin M.D., Ph.D.
Adres: 369 South San Antonio Road
Siedziba: 94022 Los Altos
ISIN: US02157Q1094
Opis firmy:

Alto Neuroscience, Inc. działa jako firma biofarmaceutyczna na stadium klinicznym, która angażuje się w działalność rozwoju leków psychiatrycznych. Firma opracowuje ALTO-100 w leczeniu pacjentów z poważnym zaburzeniem depresyjnym (MDD) i zespołem stresu pourazowego; ALTO-300, mała cząsteczka melatonergiczna agonista i serotonergiczny antagonista o właściwościach przeciwdepresyjnych w leczeniu pacjentów z MDD; oraz ALTO-101, nowy inhibitor fosfodiesterazy o małej cząsteczce do leczenia zaburzeń poznawczych związanych ze schizofrenią. Opracowuje również ALTO-203, nowatorski odwrotny agonista receptora histaminy H3 o małym cząsteczce do leczenia pacjentów z MDD i wyższym poziomem anhedonii oraz ALTO-202, badań doustnie biovilakblable antagonistę podjednostki GLUN2B podjednostki NMDA w leczeniu MDD. Ponadto firma opracowuje nowe synergistyczne kombinacje farmakodynamicznie i platformę biomarkerową obsługującą AI, która łączy źródła informacji o aktywności mózgu pacjentów w celu zidentyfikowania pacjentów w celu reagowania na nowych kandydatów produktów. Alto Neuroscience, Inc. został zarejestrowany w 2019 roku i ma siedzibę w Los Altos w Kalifornii.

Wskaźniki finansowe
Kapitalizacja (USD) 70 793 615
Aktywa: 191 608 000
Cena: 2.62
Wskaźnik Altman Z-Score: 1.5
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -1.1
Ilość akcji w obrocie: 20%
Średni wolumen: 273 068
Ilość akcji 27 072 128
Wskaźniki finansowe
Przychody TTM 372 000
Zobowiązania: 26 556 000
Przedział 52 tyg.: 1.6 - 17.55
Piotroski F-Score: 4
Umiarkowany (średnia jakość finansowa)
EPS: -2.3
P/E branży: 26.1
Beta: 0.0
Raport okresowy: 2025-08-14
WWW: https://www.altoneuroscience.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Dr. Amit Etkin M.D., Ph.D. Founder, Chairman of the Board, Chief Executive Officer & President 705 653 1977
Mr. Nicholas C. Smith Chief Financial Officer & Secretary 624 125 1989
Mr. Adam Savitz M.D., Ph.D. Chief Medical Officer 579 569 1966
Ms. Erin R. McQuade J.D. General Counsel & Chief Administrative Officer 0 1975
Mr. Jason Hoffman Vice President of Human Resources 0 0
Ms. Jessica Powell Chief Development Officer 0 1975
Mr. Fadi Abdel M.D. Senior Vice President of Innovation 0 1979
Mr. Michael C. Hanley M.B.A. Chief Operating Officer 0 1973
Ms. Melissa Berman Vice President of Finance & Accounting 0 1980
Wiadomości dla Alto Neuroscience, Inc.
Tytuł Treść Źródło Aktualizacja Link
Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. “In the first quarter of 2025 we took important steps to deliver on our clinical and corporate objectives,” said Am. businesswire.com 2025-05-14 20:10:00 Czytaj oryginał (ang.)
Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple presentations at the Society of Biological Psychiatry (SOBP) Annual Meeting, in Toronto, Canada, held April 24-26, 2025. “The biological and clinical insights we presented at SOBP support our precision psychiatry pipeline and mark important advancements for. businesswire.com 2025-04-28 12:03:00 Czytaj oryginał (ang.)
Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the JonesResearch Virtual CNS Day on Tuesday, April 29, 2025, at 12:30 pm ET and participate in one-on-one investor meetings. The presentation will be accessible via a live webcast on the Events and Presen. businesswire.com 2025-04-22 12:03:00 Czytaj oryginał (ang.)
Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the full-year ended December 31, 2024, and highlighted recent progress across its pipeline of clinical-stage product candidates. “In 2024 we continued to advance our mission to change the way medicines are developed for neuropsychiatric conditio. businesswire.com 2025-03-20 18:10:00 Czytaj oryginał (ang.)
An Investigation Has Been Launched Into Alto Neuroscience, Inc. For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com 2025-03-02 13:00:00 Czytaj oryginał (ang.)
The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com 2025-03-01 13:00:00 Czytaj oryginał (ang.)
An Investigation Has Been Launched Into Alto Neuroscience, Inc. For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / February 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com 2025-02-28 13:00:00 Czytaj oryginał (ang.)
The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation LOS ANGELES, CA / ACCESS Newswire / February 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com 2025-02-27 12:00:00 Czytaj oryginał (ang.)
An Investigation Has Been Launched Into Alto Neuroscience, Inc. For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / February 26, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com 2025-02-26 12:00:00 Czytaj oryginał (ang.)
The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation LOS ANGELES, CA / ACCESS Newswire / February 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com 2025-02-25 12:00:00 Czytaj oryginał (ang.)
Alto Neuroscience to Participate in Upcoming Investor Conferences MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events in March: TD Cowen 45th Annual Health Care Conference, March 3-5th 2025: Format: Presentation and one-on-one investor meetings Presentation Date/Time:. businesswire.com 2025-02-25 10:03:00 Czytaj oryginał (ang.)
An Investigation Has Been Launched Into Alto Neuroscience, Inc. For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / February 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com 2025-02-24 12:00:00 Czytaj oryginał (ang.)
The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation LOS ANGELES, CA / ACCESS Newswire / February 23, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com 2025-02-23 12:00:00 Czytaj oryginał (ang.)
An Investigation Has Been Launched Into Alto Neuroscience, Inc. For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / February 22, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com 2025-02-22 12:00:00 Czytaj oryginał (ang.)
The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com 2025-02-21 13:00:00 Czytaj oryginał (ang.)
Alto Neuroscience, Inc. Is Being Investigated For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com 2025-02-20 13:00:00 Czytaj oryginał (ang.)
The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation LOS ANGELES, CA / ACCESS Newswire / February 19, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com 2025-02-19 13:00:00 Czytaj oryginał (ang.)
Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has granted U.S. Patent Number 12,226,375, with method claims pertaining to treatment of major depressive disorder (MDD) in patients with inadequate response to an antidepressant. The method includes treatment with ALTO-300. businesswire.com 2025-02-19 10:03:00 Czytaj oryginał (ang.)
Alto Neuroscience, Inc. Is Being Investigated For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / February 18, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com 2025-02-18 13:00:00 Czytaj oryginał (ang.)
The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation LOS ANGELES, CA / ACCESS Newswire / February 17, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com 2025-02-17 13:00:00 Czytaj oryginał (ang.)
Alto Neuroscience, Inc. Is Being Investigated For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / February 16, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com 2025-02-16 13:00:00 Czytaj oryginał (ang.)
The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation LOS ANGELES, CA / ACCESS Newswire / February 15, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com 2025-02-15 13:00:00 Czytaj oryginał (ang.)
Alto Neuroscience, Inc. Is Being Investigated For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / February 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com 2025-02-14 13:00:00 Czytaj oryginał (ang.)
The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation LOS ANGELES, CA / ACCESS Newswire / February 13, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com 2025-02-13 13:00:00 Czytaj oryginał (ang.)
The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation LOS ANGELES, CA / ACCESS Newswire / February 11, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com 2025-02-11 13:00:00 Czytaj oryginał (ang.)
Alto Neuroscience, Inc. Is Being Investigated For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com 2025-02-10 13:00:00 Czytaj oryginał (ang.)
The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation LOS ANGELES, CA / ACCESS Newswire / February 9, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com 2025-02-09 13:00:00 Czytaj oryginał (ang.)
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / January 4, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2025-01-04 13:00:00 Czytaj oryginał (ang.)
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Alto Neuroscience Inc For Securities Fraud LOS ANGELES, CA / ACCESSWIRE / January 3, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2025-01-03 15:30:00 Czytaj oryginał (ang.)
Alto Neuroscience, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / January 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2025-01-02 15:15:00 Czytaj oryginał (ang.)
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Alto Neuroscience Inc For Securities Fraud LOS ANGELES, CA / ACCESSWIRE / December 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-12-31 13:30:00 Czytaj oryginał (ang.)
Alto Neuroscience, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / December 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-12-30 15:15:00 Czytaj oryginał (ang.)
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Alto Neuroscience Inc For Securities Fraud LOS ANGELES, CA / ACCESSWIRE / December 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-12-29 14:45:00 Czytaj oryginał (ang.)
Alto Neuroscience, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Encouraged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / December 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-12-28 14:30:00 Czytaj oryginał (ang.)
The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Alto Neuroscience Inc For Securities Fraud LOS ANGELES, CA / ACCESSWIRE / December 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-12-27 14:15:00 Czytaj oryginał (ang.)
Alto Neuroscience, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Invited To Contact The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / December 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-12-26 13:45:00 Czytaj oryginał (ang.)
The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Alto Neuroscience Inc For Securities Fraud LOS ANGELES, CA / ACCESSWIRE / December 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-12-24 13:15:00 Czytaj oryginał (ang.)
Alto Neuroscience, Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Invited To Contact The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / December 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-12-23 12:30:00 Czytaj oryginał (ang.)
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Alto Neuroscience Inc For Securities Fraud LOS ANGELES, CA / ACCESSWIRE / December 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-12-21 14:15:00 Czytaj oryginał (ang.)
Alto Neuroscience, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Invited To Contact The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / December 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-12-20 15:30:00 Czytaj oryginał (ang.)
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Alto Neuroscience Inc For Securities Fraud LOS ANGELES, CA / ACCESSWIRE / December 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-12-19 12:45:00 Czytaj oryginał (ang.)
Alto Neuroscience Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Invited To Contact The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / December 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-12-18 15:15:00 Czytaj oryginał (ang.)
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud LOS ANGELES, CA / ACCESSWIRE / December 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-12-17 15:45:00 Czytaj oryginał (ang.)
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Investors With Losses Are Invited To Contact The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-12-16 19:15:00 Czytaj oryginał (ang.)
The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud LOS ANGELES, CA / ACCESSWIRE / December 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-12-15 15:45:00 Czytaj oryginał (ang.)
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Invited To Contact The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / December 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-12-14 19:15:00 Czytaj oryginał (ang.)
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Possible Securities Fraud LOS ANGELES, CA / ACCESSWIRE / December 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com 2024-12-13 16:15:00 Czytaj oryginał (ang.)